Let’s start up with the current stock price of Kazia Therapeutics Limited (KZIA), which is $4.67 to be very precise. The Stock rose vividly during the last session to $5.12 after opening rate of $5.12 while the lowest price it went was recorded $4.50 before closing at $5.27.Recently in News on June 17, 2022, US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER. Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Kazia’s paxalisib for the treatment of atypical rhabdoid / teratoid tumors (AT/RT), a rare and highly-aggressive childhood brain cancer. You can read further details here
Kazia Therapeutics Limited had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $8.79 on 01/05/22, with the lowest value was $4.50 for the same time period, recorded on 06/21/22.
Kazia Therapeutics Limited (KZIA) full year performance was -52.73%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Kazia Therapeutics Limited shares are logging -61.97% during the 52-week period from high price, and -6.79% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $5.01 and $12.28.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 599542 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Kazia Therapeutics Limited (KZIA) recorded performance in the market was -44.54%, having the revenues showcasing -26.34% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 61.78M, as it employees total of 12 workers.
Kazia Therapeutics Limited (KZIA) in the eye of market guru’s
During the last month, 0 analysts gave the Kazia Therapeutics Limited a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 6.63, with a change in the price was noted -1.58. In a similar fashion, Kazia Therapeutics Limited posted a movement of -25.28% for the period of last 100 days, recording 164,568 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for KZIA is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Kazia Therapeutics Limited (KZIA): Stocks Technical analysis and Trends
Raw Stochastic average of Kazia Therapeutics Limited in the period of last 50 days is set at 4.20%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 6.88%. In the last 20 days, the company’s Stochastic %K was 10.84% and its Stochastic %D was recorded 12.96%.
If we look into the earlier routines of Kazia Therapeutics Limited, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -44.54%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -38.54%, alongside a downfall of -52.73% for the period of the last 12 months. The shares increased approximately by -18.07% in the 7-day charts and went up by -21.11% in the period of the last 30 days. Common stock shares were lifted by -26.34% during last recorded quarter.